1. Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting
- Author
-
Beata Olejnicka, Magnus Alexander Bitsch, Elisabeth Wreford Andersen, Nina S. Godtfredsen, Sjur Humerfelt, Peter Lange, Leif Bjermer, Dan Curiac, Gunilla Telg, Helene Nordahl Christensen, and Bo-Anders Paradis
- Subjects
Pulmonary and Respiratory Medicine ,Pediatrics ,medicine.medical_specialty ,Exacerbation ,patient satisfaction ,Population ,dyspnoea ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Quality of life ,Observational study ,Dyspnoea ,medicine ,COPD ,Patient reported outcomes ,dyspnea ,LAMA ,observational study ,030212 general & internal medicine ,education ,lcsh:RC705-779 ,education.field_of_study ,Patient-reported outcomes ,biology ,business.industry ,lcsh:Diseases of the respiratory system ,Lama ,biology.organism_classification ,medicine.disease ,030228 respiratory system ,patient-reported outcomes ,Population study ,Original Article ,business ,Progressive disease - Abstract
Introduction : Chronic obstructive pulmonary disease (COPD) is a progressive disease with symptoms that can have a major impact on patients’ physical health. The aim of this study was to evaluate quality of life (QoL), symptom severity and dyspnoea in COPD patients treated with aclidinium up to 24 weeks. Methods : In this prospective non-interventional multicentre study (198 centres in Sweden, Denmark, and Norway), COPD patients (age ≥40 years) who started treatment with aclidinium (initial therapy, change of treatment, or add-on therapy) could be included. Health-related QoL was obtained by COPD assessment test (CAT). Symptoms were evaluated on a 6-point Likert scale. The modified Medical Research Council (mMRC) Dyspnoea Scale was used as a simple grading system to assess the level of dyspnoea/shortness of breath from0 to 4. Patients on treatment with aclidinium who completed baseline and at least one follow-up visit (week 12 or 24) were included in the study population. Results : Overall, 1,093 patients were enrolled (mean 69 years, 54% females), one-third had ≥1 exacerbation the year prior to baseline. At enrolment, 48% were LAMA naive. Mean (standard deviation, SD) CAT score decreased from 16.9 (7.7) at baseline to 14.3 (7.3) at week 24 ( p
- Published
- 2016
- Full Text
- View/download PDF